View Older Stories

May 29, 2026 08:01AM Replimune plans RP1 cancer drug resubmission after FDA talks

May 29, 2026 07:33AM Replimune To Resubmit Melanoma Treatment For Fda Approval - WSJ

May 12, 2026 12:50PM FDA Commissioner Marty Makary is resigning - Politico reporter on X

May 8, 2026 01:32PM Replimune shares surge on report Trump to dismiss FDA chief Makary

Apr 14, 2026 10:44AM Increasing unusual option volume: REPL ALLO CORN ALMU IDYA TPG CNK PLCE IVR VIST TVTX

Apr 13, 2026 10:15AM Increasing unusual option volume: REPL ALLO CORN ALMU IDYA TPG CNK PLCE IVR VIST TVTX

Apr 13, 2026 03:41AM BMO Capital Downgrades Replimune Group (REPL) to Underperform

Apr 13, 2026 03:41AM Jefferies Downgrades Replimune Group (REPL) to Hold

Apr 13, 2026 01:54AM JPMorgan Downgrades Replimune Group (REPL) to Underweight

Apr 10, 2026 05:04PM Replimune receives FDA rejection for melanoma treatment RP1

Apr 10, 2026 04:16PM Cantor Fitzgerald Downgrades Replimune Group (REPL) to Neutral

Apr 10, 2026 03:38PM Piper Sandler Downgrades Replimune Group (REPL) to Neutral

Apr 10, 2026 01:20PM Jefferies on Iovanace Biotherapeutics (IOVA): 'we think the pot'l risk of competition was accounted for in Street models'

Apr 10, 2026 11:19AM Replimune (REPL) gets CRL from FDA

Apr 10, 2026 10:57AM Replimune (REPL) Halted on Volatility, Down 8%

Apr 5, 2026 10:29AM Increasing unusual option volume: VFS CORN CODI BIZD CWAN REPL

Feb 4, 2026 06:54AM Replimune Group, Inc. (REPL) Misses Q3 EPS by 1c

Nov 12, 2025 07:43AM Replimune's (REPL) RP1s Likely to Get Accelerated Approval - Cantor Fitzgerald

Nov 7, 2025 04:45PM Replimune presents RP1 melanoma trial data at cancer meeting

Nov 3, 2025 12:04AM BMO Capital Upgrades Replimune Group (REPL) to Market Perform

Oct 27, 2025 06:44AM H.C. Wainwright Upgrades Replimune Group (REPL) to Buy

Oct 20, 2025 02:52PM JPMorgan Upgrades Replimune Group (REPL) to Neutral

Oct 20, 2025 02:27PM Replimune (REPL) call put ratio 1.2 calls to 1 put as share price up 105%

Oct 20, 2025 10:20AM Leerink Partners Upgrades Replimune Group (REPL) to Outperform

Oct 20, 2025 10:02AM Increasing unusual put option volume: REPL LBRT ARCT CRML BYND ABAT BITF EXEL

Oct 20, 2025 08:59AM Wedbush Upgrades Replimune Group (REPL) to Outperform

Oct 20, 2025 07:02AM FDA accepts Replimune BLA resubmission for RP1 melanoma treatment

Sep 19, 2025 06:51AM H.C. Wainwright Reiterates Neutral Rating on Replimune Group (REPL)

Sep 19, 2025 02:13AM JPMorgan Downgrades Replimune Group (REPL) to Underweight

Sep 18, 2025 09:15AM Replimune meets with FDA on melanoma treatment application

Sep 9, 2025 06:50AM H.C. Wainwright Reiterates Neutral Rating on Replimune Group (REPL)

Sep 2, 2025 08:02AM Replimune schedules FDA meeting on melanoma treatment application

Aug 11, 2025 05:30AM Replimune Group (REPL) PT Lowered to $8 at Jefferies

Jul 31, 2025 02:12PM Important Notice to Long-term Shareholders of Replimune Group, Inc. (REPL): Grabar Law Office Investigates Claims on Your Behalf

Jul 31, 2025 05:01AM Increasing unusual option volume: SMCY REPL ROIV PARA CRDF OPEN CWH PAGP LC CP

Jul 30, 2025 01:43PM Cantor Fitzgerald Upgrades Replimune Group (REPL) to Overweight

Jul 30, 2025 10:03AM Increasing unusual option volume: REPL CP PGEN CRDF LC INDA NEO TTI JBS HOG TER

Jul 29, 2025 03:19PM Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman

Jul 23, 2025 06:06AM H.C. Wainwright Downgrades Replimune Group (REPL) to Neutral

Jul 23, 2025 06:00AM Increasing unusual put option volume: OPEN REPL NOK AAOI GRPO ATYR HPP ETHE

Jul 23, 2025 12:29AM BMO Capital Downgrades Replimune Group (REPL) to Underperform

Jul 22, 2025 04:31PM Barclays Downgrades Replimune Group (REPL) to Equalweight

Jul 22, 2025 01:19PM Leerink Partners Downgrades Replimune Group (REPL) to Market Perform

Jul 22, 2025 12:31PM Leerink Partners Reiterates Outperform Rating on Replimune Group (REPL), PT $21, 'Estimates Under Review'

Jul 22, 2025 11:18AM Replimune Group (REPL) PT Lowered to $6 at Jefferies, Buy rating kept, 'see the reasonable case as accelerated approval based on interim results'

Jul 22, 2025 10:30AM Increasing unusual option volume: REPL OPEN PGEN NXDR UPXI UGL AAOI

Jul 22, 2025 09:50AM Wedbush Downgrades Replimune Group (REPL) to Neutral

Jul 22, 2025 09:15AM Replimune Group Stock Drops More Than 75% on News of FDA Complete Response Letter - Kehoe Law Firm, P.C. Investigating Securities Claims on Behalf of Investors - REPL

Jul 22, 2025 09:09AM Cantor Fitzgerald Downgrades Replimune Group (REPL) to Neutral, Only Firm Thus Far Not Buy/Overweight Rated

Jul 22, 2025 08:53AM BMO Capital Reiterates Outperform Rating on Replimune Group (REPL), PT $27, 'we see a long road ahead'

View Older Stories